Cidofovir
Top View
- 1078-0432.CCR-17-0040.Full.Pdf
- 2012 NIOSH List of Antineoplastic and Other Hazardous Drugs
- Vistide, INN – Cidofovir
- Vistide® 41 Randomized to 3 Mg/Kg)
- The Mechanism of Drug Nephrotoxicity and the Methods for Preventing Kidney Damage
- Cidofovir (Vistide®)
- Case Report Treatment of an Acyclovir and Foscarnet-Resistant Herpes Simplex Virus Infection with Cidofovir in a Child After an Unrelated Bone Marrow Transplant
- E2021579118.Full.Pdf
- Complex Management of Resistant Oral Herpes Simplex Virus Infection Following Hematopoietic Stem Cell Transplantation: Potential Role of Topical Cidofovir
- Drug Discovery of Nucleos(T)Ide Antiviral Agents: Dedicated to Prof. Dr. Erik De Clercq on Occasion of His 80Th Birthday
- Valganciclovir.Pdf
- Valganciclovir—Ganciclovir Use and Systematic Therapeutic Drug Monitoring
- Case Report Progressive Multifocal Leukoencephalopathy After Stem Cell Transplantation, Unsuccessfully Treated with Cidofovir
- Effectiveness of Cidofovir in Treating Natalizumab-Associated Progressive Multifocal Leukoencephalopathy (PML)
- Successful Treatment of Acyclovir-Resistant Herpes Simplex Virus with Intralesional Cidofovir
- ANTIRETROVIRAL CONTRAINDICATIONS and DRUG INTERACTIONS (Part of 5)
- Evaluation of Carcinogenicity Studies of Medicinal Products for Human Use Authorised Via the European Centralised Procedure
- Viral Infections